156 related articles for article (PubMed ID: 15107207)
1. Management of endocrine resistant breast cancer.
Sundar S; Decatris MP; O'Byrne KJ
J Br Menopause Soc; 2004 Mar; 10(1):16-23. PubMed ID: 15107207
[TBL] [Abstract][Full Text] [Related]
2. Management of metastatic breast cancer: monotherapy options for patients resistant to anthracyclines and taxanes.
Rivera E
Am J Clin Oncol; 2010 Apr; 33(2):176-85. PubMed ID: 19675449
[TBL] [Abstract][Full Text] [Related]
3. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
Conte P; Guarneri V; Bengala C
Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
[TBL] [Abstract][Full Text] [Related]
6. The curability of breast cancer and the treatment of advanced disease.
Guarneri V; Conte PF
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
[TBL] [Abstract][Full Text] [Related]
7. Platinum compounds in the treatment of advanced breast cancer.
Martín M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
8. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
Hortobagyi GN; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Lerzo GL; Pivot XB; Hurtado de Mendoza F; Xu B; Vahdat LT; Peck RA; Mukhopadhyay P; Roché HH
Breast Cancer Res Treat; 2010 Jul; 122(2):409-18. PubMed ID: 20454927
[TBL] [Abstract][Full Text] [Related]
9. Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
Halterman PA
Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221
[TBL] [Abstract][Full Text] [Related]
10. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
11. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
Ravdin PM
Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
[TBL] [Abstract][Full Text] [Related]
12. Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer.
Perez EA
Breast Cancer Res Treat; 2009 Mar; 114(2):195-201. PubMed ID: 18443902
[TBL] [Abstract][Full Text] [Related]
13. Ixabepilone: clinical role in metastatic breast cancer.
Denduluri N; Swain S
Clin Breast Cancer; 2011 Jun; 11(3):139-45. PubMed ID: 21665133
[TBL] [Abstract][Full Text] [Related]
14. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
[TBL] [Abstract][Full Text] [Related]
15. Algorithms for the treatment of patients with metastatic breast cancer and prior exposure to taxanes and anthracyclines.
Comen EA; Fornier MN
Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S7-19. PubMed ID: 20805067
[TBL] [Abstract][Full Text] [Related]
16. Vinorelbine With Capecitabine, an Evergreen Doublet for Advanced Breast Cancer: A Systematic Literature Review and Pooled-Analysis of Phase II-III Studies.
Petrelli F; Di Cosimo S; Lonati V; Barni S
Clin Breast Cancer; 2016 Oct; 16(5):327-334. PubMed ID: 27282844
[TBL] [Abstract][Full Text] [Related]
17. Implications of anthracycline-resistant and taxane-resistant metastatic breast cancer and new therapeutic options.
Rivera E
Breast J; 2010; 16(3):252-63. PubMed ID: 20408828
[TBL] [Abstract][Full Text] [Related]
18. HER2-positive metastatic breast cancer: a changing scenario.
Mustacchi G; Biganzoli L; Pronzato P; Montemurro F; Dambrosio M; Minelli M; Molteni L; Scaltriti L
Crit Rev Oncol Hematol; 2015 Jul; 95(1):78-87. PubMed ID: 25748080
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients.
Zhang P; Tong Z; Tian F; Wang Y; Yang J; Li W; Di L; Liu W; Tang L; Qiu R; Xu B
J Hematol Oncol; 2016 Aug; 9(1):68. PubMed ID: 27516093
[TBL] [Abstract][Full Text] [Related]
20. Survival data of patients with anthracycline- or taxane-pretreated or resistant metastatic breast cancer.
Barnett CM
Pharmacotherapy; 2009 Dec; 29(12):1482-90. PubMed ID: 19947807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]